



L is independently selected from $-C(R)(R'')$, $-CO-$, and $-NR''$;

n is zero, one, two, three, four, five, six, seven, eight, nine or ten;

R and R'' are independently selected from hydrogen and alkyl;

D is independently selected from $-C(R_9)-$, wherein R_9 is hydrogen; and $-N-$;

A_1 , A_2 , A_3 , A_4 , A_5 , A_7 , A_8 , are independently selected from $-C(R_{10})(R_{11})-$ and $=C(R_{10})-$;

each of E and G is, independently, $-CO-$ or $-CH_2-$;

R_1 , R_2 , R_3 , and R_4 , are independently selected from hydrogen and alkoxy; and

R_{10} and R_{11} are independently selected from hydrogen and halo;

20. (Previously Presented) A compound according to claim 19, wherein X is selected from phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl), 1-indanon-2-yl, and indandion-2-yl.

21. (Previously Presented) A compound according to claim 19, wherein X is phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl) and the cyclic part of formula I represents 9-acridinyl, 1,2,3,4-tetrahydro-acridin-9-yl or 6-chloro, 1,2,3,4-tetrahydro-acridin-9-yl.

22. (Previously Presented) A compound according to claim 19 which is:

- 2-[6-(acridin-9-ylamino)-hexyl]-isoindole-1,3-dione (6),
- 2-[7-(acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (7),
- 2-[8-(acridin-9-ylamino)-octyl]-isoindole-1,3-dione (8),
- 2-[9-(acridin-9-ylamino)-nonyl]-isoindole-1,3-dione (9),

- N-[7-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (10),
- N-(3-{[3-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-propyl]-methyl-amino}-propyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (11),
- N-[6-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (12),
- 2-[6-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-hexylamino]-indan-1,3-dione (3),
- 2-[7-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (4), or
- 2-[8-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-octyl]-isoindole-1,3-dione (5).

23. (Previously Presented) A compound according to claim 19, wherein X is 1-indanon-2-yl and the cyclic part of formula I represents 1,2,3,4-tetrahydro-acridin-9-yl.

24. (Previously Presented) A compound according to claim 23, which is:
- 5,6-Dimethoxy-2-{{[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptylamino]-methyl}-indan-1-one (1) or
 - 5,6-Dimethoxy-2-{{[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexylamino]-methyl}-indan-1-one (2).

25. (Previously Presented) A pharmaceutical formulation containing as active ingredient a compound as defined in claim 19.

26. (Withdrawn) A method of treating a cognitive disorder, which comprises administering an effective amount of a compound as defined in claim 19.

27. (Withdrawn) The method of claim 26, wherein the cognitive disorder is senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, or a neurodegenerative dementing disease with aberrant protein aggregations.

28. (Withdrawn) The method of claim 27, wherein the neurodegenerative dementing disease with aberrant protein aggregations is Alzheimer's disease, Parkinson disease, ALS, or prion diseases.

29. (Withdrawn) The method of claim 28, wherein the prion disease is Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.